JOANNA YI to Humans
This is a "connection" page, showing publications JOANNA YI has written about Humans.
Connection Strength
0.126
-
A report from the Leukemia Electronic Abstraction of Records Network on risk of hepatotoxicity during pediatric acute lymphoblastic leukemia treatment. Haematologica. 2022 05 01; 107(5):1185-1188.
Score: 0.017
-
Defining the transcriptional control of pediatric AML highlights RARA as a superenhancer-regulated druggable dependency. Blood Adv. 2021 12 14; 5(23):4864-4876.
Score: 0.016
-
The synergy of BET inhibitors with aurora A kinase inhibitors in MYCN-amplified neuroblastoma is heightened with functional TP53. Neoplasia. 2021 06; 23(6):624-633.
Score: 0.016
-
Synchronous occurrence of acute lymphoblastic leukemia and wilms tumor in two patients: underlying etiology and combined treatment plan. Pediatr Blood Cancer. 2017 05; 64(5).
Score: 0.011
-
A novel APC gene mutation associated with a severe phenotype in a patient with Turcot syndrome. J Pediatr Hematol Oncol. 2014 Apr; 36(3):e177-9.
Score: 0.010
-
Homozygous alpha-thalassemia treated with intrauterine transfusions and unrelated donor hematopoietic cell transplantation. J Pediatr. 2009 May; 154(5):766-8.
Score: 0.007
-
Tazemetostat for tumors harboring SMARCB1/SMARCA4 or EZH2 alterations: results from NCI-COG pediatric MATCH APEC1621C. J Natl Cancer Inst. 2023 11 08; 115(11):1355-1363.
Score: 0.005
-
Discovery of potent BET bromodomain 1 stereoselective inhibitors using DNA-encoded chemical library selections. Proc Natl Acad Sci U S A. 2022 05 31; 119(22):e2122506119.
Score: 0.004
-
Novel CIC variants identified in individuals with neurodevelopmental phenotypes. Hum Mutat. 2022 07; 43(7):889-899.
Score: 0.004
-
A distinct core regulatory module enforces oncogene expression in KMT2A-rearranged leukemia. Genes Dev. 2022 03 01; 36(5-6):368-389.
Score: 0.004
-
An oncogenic enhancer encodes selective selenium dependency in AML. Cell Stem Cell. 2022 03 03; 29(3):386-399.e7.
Score: 0.004
-
Phase II Trial of Inotuzumab Ozogamicin in Children and Adolescents With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: Children's Oncology Group Protocol AALL1621. J Clin Oncol. 2022 03 20; 40(9):956-967.
Score: 0.004
-
Gilteritinib combination therapies in pediatric patients with FLT3-mutated acute myeloid leukemia. Blood Adv. 2021 12 14; 5(23):5215-5219.
Score: 0.004
-
Bromodomain and extra-terminal?inhibitors-A consensus prioritisation after the Paediatric Strategy Forum for medicinal product development of epigenetic modifiers in children-ACCELERATE. Eur J Cancer. 2021 03; 146:115-124.
Score: 0.004
-
Novel Src/Abl tyrosine kinase inhibitor bosutinib suppresses neuroblastoma growth via inhibiting Src/Abl signaling. Oncotarget. 2017 Jan 03; 8(1):1469-1480.
Score: 0.003
-
Novel MDM2 inhibitor SAR405838 (MI-773) induces p53-mediated apoptosis in neuroblastoma. Oncotarget. 2016 Dec 13; 7(50):82757-82769.
Score: 0.003
-
Multiple CDK inhibitor dinaciclib suppresses neuroblastoma growth via inhibiting CDK2 and CDK9 activity. Sci Rep. 2016 07 05; 6:29090.
Score: 0.003
-
A Prospective Cohort Quality Improvement Study to Reduce the Time to Antibiotics for New Fever in Neutropenic Pediatric Oncology Inpatients. Pediatr Blood Cancer. 2016 Jan; 63(1):112-7.
Score: 0.003
-
Structure-guided DOT1L probe optimization by label-free ligand displacement. ACS Chem Biol. 2015 Mar 20; 10(3):667-74.
Score: 0.003
-
Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors. Nat Commun. 2012; 3:1288.
Score: 0.002